Releases - Biotec Pharmacon ASA

View:
 

Found press releases

 

ArcticZymes granted patents covering the heat-labile DNase product family

3/1/2013 5:04 AM EST
ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA, has received an acceptance for the South African patent application covering its heat-labile DNase product.

With the approval of a new patent in South Africa, ArcticZymes is adding a new patent family with approved patents to its existing intellectual property portfolio. Additional patent applications are pending in the main markets including Europe, USA and...

BIOTEC – Raises NOK 40 million in a private placement

1/11/2013 2:10 AM EST
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES Tromsø, Norway, 11 January 2013 Biotec Pharmacon ASA ("Biotec" or the "Company", ticker "BIOTEC") today announces that the Company has raised NOK 40 million in gross proceeds through a private placement of 9,500,000 new shares, each with a par value of NOK 1.00 at a price of...

Biotec Betaglucans signs evaluation agreement with Smith & Nephew

12/21/2012 8:27 AM EST
Biotec BetaGlucans AS, a wholly-owned subsidiary of Biotec Pharmacon ASA, today announces that  it has signed an agreement with Smith & Nephew plc (LSE: SN, NYSE: SNN) to cooperate on a market evaluation of Woulgan® Biogel.
Woulgan® Biogel is a new bioactive treatment for use on chronic wounds. It has successfully completed phase II trials and is expected to attain CE mark in 2013. At this point Biotec...

Biotec BetaGlucans receives promising results from animal study

11/16/2012 9:58 AM EST
Biotec BetaGlucans AS, a fully owned subsidiary of Biotec Pharmacon ASA, has received an interim data report from the fourth animal study in diabetic mice. An important goal with this study was to investigate the wound healing efficacy of large scale production batches, also including the first validation batch from June 2012. Included in the study was also experimental dry dressing products wherein SBG (soluble...

ArcticZymes Signs Enzyme Supply Agreement with New England Biolabs

11/2/2012 5:01 AM EST
Tromsø, Norway, 2 November 2012 – ArcticZymes AS, the Tromsø-based manufacturer of innovative heat-labile molecular biology enzymes, has signed a supply agreement with New England Biolabs Inc. (NEB) for the supply of Recombinant Shrimp Alkaline Phosphatase (SAP) from ArcticZymes.  NEB plans to offer SAP through its global distribution network. The agreement also allows for the introduction of other ArcticZymes’...

ArcticZymes® AS strengthens its Sales & Marketing force

10/9/2012 6:12 AM EST
ArcticZymes® is pleased to announce the hiring of Mr. Dino DiCamillo in a temporary position as worldwide Director of Sales and Marketing. DiCamillo has more than 30 years experience as a commercial and operational leader in the research and diagnostic industry and a proven track record in business development, key account strategy and management, OEM sales, and end-user marketing activities.

Woulgan®Biogel available for professional wound and ulcer treatment in 2013

10/1/2012 5:15 AM EST
The company Biotec BetaGlucans AS in Tromsø, Norway, has developed a new product - Woulgan® Biogel – which effectively enhances the body’s own ability to heal wounds and ulcers, and which may shorten the treatment time for ulcers and slow-healing wounds.
There is a pressing need for more effective treatments of painful and often debilitating ulcers and slowly healing wounds, and today there are no medical...

Woulgan® Trademark Registered in Main Jurisdictions

8/28/2012 5:21 AM EST
Biotec Pharmacon’s Product Woulgan® Is Now Protected By Trademarks In Major Countries And Regions
TROMSØ, NORWAY, August 28, 2012 – Biotec Pharmacon ASA (OSE: BIOTEC) announced today the positive registration of trademark applications for Woulgan®by several international patent and trademark offices.

As a further milestone in the development of the Woulgan® concept, Biotec Pharmacon is proud to announce the...

Completed filing of Technical Dossier for Woulgan®

7/19/2012 6:57 AM EST
Biotec Pharmacon confirms that the non medicinal part of the Dossier for Woulgan® has been filed to the Notified Body as scheduled in the Company's announcement from July 6th. This completes the filing of the Dossier for Woulgan® to the Notified Body, DNV Nemko Presafe AS and to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for their review and approval. When approved, a CE-Mark will be issued...

SAP Patent Family Entirely Approved

5/9/2012 5:14 AM EST
ArcticZymes AS finalizes its protection of the SAP patent family  

TROMSØ, NORWAY, May 9, 2012 - ArcticZymes AS, a subsidiary of Biotec Pharmacon ASA (TICKER: BIOTEC) has received a Notice of Allowance for the Norwegian patent application of the SAP-patent family.
The allowed patent covers the product and its use as well as the method of producing SAP, ArcticZymes' top-selling enzyme Shrimp Alkaline...

Biotec Pharmacon ASA

RSS